Posts

Posted on

Rocket Companies to Participate in Citi Financial Technology Virtual Conference

PR Newswire

DETROIT, Nov. 16, 2020 /PRNewswire/ — Rocket Companies, Inc. (NYSE: RKT) (“Rocket Companies” or the “Company”), a Detroit-based holding company consisting of tech-driven real estate, mortgage and financial services businesses – including Rocket Mortgage, Rocket Homes and Rocket Auto – today announced that Chief Executive Officer Jay Farner will participate in a fireside chat as part of Citi’s 2020 Financial Technology Virtual Conference beginning at 1:30 PM Eastern Time on Tuesday, November 17, 2020.

A live webcast of the event will be available online at ir.rocketcompanies.com, or by navigating to https://kvgo.com/citifintech/rocket-companies-november-2020. A replay of the webcast will be available on the Investor Relations section of the Company’s website for one year within 24 hours of the conclusion of the event.

Statements made during the webcast may include forward-looking statements about Rocket Companies. The webcast may also include information about the Company’s financial results, operations, and outlook.

About Rocket Companies
Rocket Companies is a Detroit-based holding company consisting of personal finance and consumer service brands including Rocket Mortgage, Rocket Homes, Rocket Loans, Rocket Auto, Rock Central, Amrock, Core Digital Media, Rock Connections, Lendesk and Edison Financial. Since 1985, Rocket Companies has been obsessed with helping its clients achieve the American dream of home ownership and financial freedom. Rocket Companies offers an industry-leading client experience powered by our simple, fast, and trusted digital solutions. Rocket Companies has 22,000 team members across the United States. Its flagship company, Rocket Mortgage, has been named to Fortune magazine’s list of “100 Best Companies to Work For” for 17 consecutive years. for more information, please visit our Corporate Website, Investor Relations Website, Twitter page, and our LinkedIn page.

Forward Looking Statements
Some of the statements contained in this document are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are generally identified by the use of words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. These forward-looking statements reflect our views with respect to future events as of the date of this document and are based on our management’s current expectations, estimates, forecasts, projections, assumptions, beliefs and information. Although management believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will prove to have been correct. All such forward-looking statements are subject to risks and uncertainties, many of which are outside of our control, and could cause future events or results to be materially different from those stated or implied in this document. It is not possible to predict or identify all such risks. These risks include, but are not limited to, the risk factors that are described under the section titled “Risk Factors” in our Quarterly Report on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this document and in our SEC filings. We expressly disclaim any obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by applicable law.

Investor Relations Contacts:

Jason McGruder or John Shallcross
[email protected] 
(313) 373-7990

Media Contact:

Aaron Emerson

[email protected] 
(313) 373-3035

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rocket-companies-to-participate-in-citi-financial-technology-virtual-conference-301173986.html

SOURCE Rocket Companies, Inc.

Posted on

Cedar Realty Trust Announces 1-for-6.6 Reverse Stock Split

PR Newswire

PORT WASHINGTON, N.Y., Nov. 16, 2020 /PRNewswire/ — Cedar Realty Trust, Inc. (NYSE: CDR – the “Company”) announced that its Board of Directors approved a reverse stock split of the Company’s outstanding shares of common stock at a ratio of 1-for-6.6. The reverse stock split is expected to take effect at about 9:00 a.m. Eastern time on November 27, 2020 (the “Effective Time”).

Accordingly, at the Effective Time, every six and six-tenths issued and outstanding shares of common stock will be converted into one share of common stock. In addition, at the market open on November 27, 2020, the common stock will be assigned a new CUSIP number: 150602 605.

As a result of the reverse stock split, the number of outstanding shares of common stock of the Company will be reduced from approximately 89.3 million to approximately 13.5 million. The Company expects that a corresponding adjustment will be made to its quarterly dividend. The amount of any future dividends payable by the Company will be determined by and are at the discretion of the Company’s Board of Directors.

No fractional shares will be issued in connection with the reverse stock split. Instead, each stockholder holding fractional shares will be entitled to receive, in lieu of such fractional shares, cash in an amount determined on the basis of the average closing price of the Company’s common stock on the New York Stock Exchange for the three consecutive trading days ending on November 25, 2020. The reverse stock split will apply to all of the Company’s outstanding shares of common stock. Stockholders of record will be receiving information from American Stock Transfer & Trust Company, LLC, the Company’s transfer agent, regarding their stock ownership following the reverse stock split and cash in lieu of fractional share payments, if applicable.

About Cedar Realty Trust
Cedar Realty Trust, Inc. is a fully-integrated real estate investment trust which focuses on the ownership, operation and redevelopment of grocery-anchored shopping centers in high-density urban markets from Washington, D.C. to Boston. The Company’s portfolio (excluding properties treated as “held for sale”) comprises 54 properties, with approximately 8.2 million square feet of gross leasable area.

For additional financial and descriptive information on the Company, its operations and its portfolio, please refer to the Company’s website at www.cedarrealtytrust.com.

Cision View original content:http://www.prnewswire.com/news-releases/cedar-realty-trust-announces-1-for-6-6-reverse-stock-split-301173922.html

SOURCE Cedar Realty Trust, Inc.

Posted on

Poly Grants Chief Legal Officer Lisa Bodensteiner Inducement Awards Pursuant to NYSE Rule 303A.08

PR Newswire

SANTA CRUZ, Calif., Nov. 16, 2020 /PRNewswire/ — Poly (NYSE: PLT) today announced that it has granted equity awards that were approved by the Leadership Development and Compensation Committee (the “Committee”) of Poly’s Board of Directors on October 26, 2020, as a material inducement to employment to Lisa Bodensteiner, who was appointed Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary, effective as of October 30, 2020.

The awards made to Ms. Bodensteiner are as follows. First, an award of 15,000 restricted stock units (“RSUs”) granted on November 16, 2020 (the “Award Date”), which will vest in three equal annual installments commencing on the last calendar day of the month following each anniversary of the Award Date in accordance with the Company’s Equity Processes Policy, in each case subject to Ms. Bodensteiner’s continued employment with the Company on each applicable vesting date. Second, an award of 35,000 performance stock unit awards (“PSUs”) on the Award Date. The performance period for the PSUs will be aligned to the Company’s 2021 fiscal year for performance-based RSUs (the “PSU Plan”). The PSUs will vest in accordance with the terms of the PSU Plan, subject to Ms. Bodensteiner’s continued employment with the Company through the applicable vesting date.

The awards were all granted outside of the Poly 2003 Stock Plan (but generally have terms and conditions consistent with those set forth in that plan) and were approved by the Committee in reliance on the employment inducement exemption under the NYSE’s Listed Company Manual Rule 303A.08, which requires public announcement of inducement awards. Pursuant to the requirements of that rule, Poly is issuing this press release.

About Poly
Poly (Plantronics, Inc. – formerly Plantronics and Polycom) is a global communications company that powers meaningful human connection and collaboration. Poly combines legendary audio expertise and powerful video and conferencing capabilities to overcome the distractions, complexity and distance that make communication challenging. Poly believes in solutions that make life easier when they work together and with our partners’ services. Poly is one of the global industry leaders offering headsets, video and audio conferencing, desk phones, analytics software and services. For more information visit www.Poly.com.

Poly, the propeller design, and the Poly logo are trademarks of Plantronics, Inc. All other trademarks are the property of their respective owners.

INVESTOR CONTACT:

Mike Iburg

Vice President, Investor Relations
(831) 458-7533

MEDIA CONTACT:

Edie Kissko

Vice President, Poly Communications
(213) 369-3719

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/poly-grants-chief-legal-officer-lisa-bodensteiner-inducement-awards-pursuant-to-nyse-rule-303a08-301173896.html

SOURCE Poly

Posted on

MetLife Declares Fourth Quarter 2020 Preferred Stock Dividends

MetLife Declares Fourth Quarter 2020 Preferred Stock Dividends

NEW YORK–(BUSINESS WIRE)–
MetLife, Inc. (NYSE: MET) today announced that it has declared the following preferred stock dividends:

  • Quarterly dividend of $0.25277777 per share on the company’s floating rate non-cumulative preferred stock, Series A, with a liquidation preference of $25 per share (NYSE: MET PRA).
  • Quarterly dividend of $9.66971055 per share on the company’s 5.250% fixed-to-floating rate non-cumulative preferred stock, Series C, with a liquidation preference of $1,000 per share.
  • Quarterly dividend of $351.5625 per share on the company’s 5.625% non-cumulative preferred stock, Series E, with a liquidation preference of $25,000 per share, represented by depositary shares each representing 1/1,000th interest in a share of the preferred stock, holders of which will receive $0.3515625 per depositary share (NYSE: MET PRE).
  • Quarterly dividend of $296.875 per share on the company’s 4.75% non-cumulative preferred stock, Series F, with a liquidation preference of $25,000 per share, represented by depositary shares each representing 1/1,000th interest in a share of the preferred stock, holders of which will receive $0.296875 per depositary share (NYSE: MET PRF).

The above dividends will be payable on Dec. 15, 2020, to shareholders of record as of Nov. 30, 2020.

About MetLife

MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates (“MetLife”), is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management to help its individual and institutional customers navigate their changing world. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Japan, Latin America, Asia, Europe and the Middle East. For more information, visit www.metlife.com.

Forward-Looking Statements

The forward-looking statements in this news release, such as “will,” are based on assumptions and expectations that involve risks and uncertainties, including the “Risk Factors” MetLife, Inc. describes in its U.S. Securities and Exchange Commission filings. MetLife’s future results could differ, and it has no obligation to correct or update any of these statements.

For Media:

Meredith Hyland

(212) 578-9415

[email protected]

For Investors:

John Hall

(212) 578-7888

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Banking Professional Services Insurance Finance

MEDIA:

Logo
Logo
Posted on

Baxter Declares Quarterly Dividend

Baxter Declares Quarterly Dividend

DEERFIELD, Ill.–(BUSINESS WIRE)–
Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that its Board of Directors has declared a quarterly cash dividend of $0.245 per share of common stock. The dividend is payable on January 4, 2021, to shareholders of record as of December 4, 2020. The indicated annual dividend rate is $0.98 per share of common stock.

About Baxter

Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.

This release includes forward-looking statements concerning the company’s capital allocation, which currently includes the issuance of quarterly dividends. These forward-looking statements are based on assumptions about many factors and it is possible that Baxter’s annual dividend payout rate may differ, possibly materially, from the anticipated annual indicative dividend described herein. For information about some of the risks and important factors that could affect Baxter’s future results, financial condition and liquidity, see Baxter’s most recent filings on Forms 10-K and 10-Q and other SEC filings, all of which are available on Baxter’s website. Baxter does not undertake to update its forward-looking statements unless otherwise required by the federal securities laws.

Baxter is a registered trademark of Baxter International Inc.

Media Contact

Steve Brett, (224) 948-5353

[email protected]

Investor Contact

Clare Trachtman, (224) 948-3020

KEYWORDS: Illinois United States North America

INDUSTRY KEYWORDS: Cardiology Biotechnology Medical Supplies Health Diabetes Medical Devices Hospitals Other Health

MEDIA:

Logo
Logo
Posted on

Zymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the CD47 Blocker ALX148 in Patients with Advanced HER2‑Expressing Breast Cancer

Zymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the CD47 Blocker ALX148 in Patients with Advanced HER2‑Expressing Breast Cancer

VANCOUVER, British Columbia & BURLINGAME, Calif.–(BUSINESS WIRE)–
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics,and ALX Oncology Holdings Inc. (NASDAQ: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced they have entered into a clinical collaboration to evaluate the combination of Zymeworks’ zanidatamab (formerly ZW25), a HER2-targeted bispecific antibody, and ALX148, a next-generation CD47 blocker, for the treatment of patients with advanced HER2-expressing breast cancer and other solid tumors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201116005959/en/

Under the terms of the agreement, Zymeworks will conduct an open label, multi-center Phase 1b study to assess the safety and efficacy of the combination of zanidatamab and ALX148 in a two-part study. The first part of the trial will evaluate the safety of the combination treatment. The second part of the trial will evaluate the safety, tolerability and anti-tumor activity of the combination in separate cohorts of subjects with HER2-positive breast cancer, HER2-low breast cancer, and non-breast HER2-expressing solid tumors.

“In addition to broad anti-tumor activity, zanidatamab’s safety profile supports combination approaches with other therapeutics,” said Diana Hausman, M.D., Chief Medical Officer at Zymeworks. “Our collaboration with ALX Oncology and their CD47 blocker, ALX148, has the potential to further expand the opportunity for zanidatamab to provide benefit to a broader population of patients, including those with advanced HER2‑expressing breast cancer.”

Zanidatamab is designed to have multiple mechanisms of action, including immune clearance of HER2-expressing tumor cells by macrophages through antibody-dependent cellular phagocytosis (ADCP). CD47 is a “don’t eat me” signal that acts as a checkpoint inhibitor to macrophages. Cancer cells that express CD47 are resistant to immune clearance even when targeted with therapeutic antibodies. Treatment with zanidatamab plus ALX148 has the potential to increase the immune clearance of HER2-expressing cancer cells by combining a biparatopic antibody capable of binding at higher density than monospecific antibodies with a molecule that blocks CD47 on the same targeted cancer cells.

“We are excited about this collaboration with Zymeworks that combines two promising next-generation anti-cancer agents, a HER2-targeted bispecific antibody with a CD47 blocker, to enhance their potential activity in treating patients with advanced breast cancer,” said Jaume Pons, Ph.D., Founder, President and Chief Executive Officer of ALX Oncology. “ALX148 was designed for safe use in combination to maximize clinical activity with a range of anti-cancer agents. This collaboration builds on the promising anti-tumor activity observed in clinical trials of ALX148 combined with a HER2-targeted therapy in patients with advanced HER2-positive gastric and gastroesophageal cancer.”

Zanidatamab is in advanced clinical development, actively enrolling a pivotal study in patients with previously-treated HER2 gene-amplified biliary tract cancer. In addition, five active Phase 2 programs are underway, and Zymeworks plans to initiate a second pivotal study for zanidatamab as first-line treatment for advanced HER2‑positive gastroesophageal adenocarcinomas.

Phase 1 studies of ALX148 have been conducted in combination with tumor antigen targeted antibodies, a checkpoint inhibitor and chemotherapy. Preliminary results from ASPEN-01, the ALX148 Phase 1b study, were presented at the Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting [abstract 404]. ALX148 displayed promising initial clinical activity in patients with solid tumors, including advanced HER2-positive gastric and gastroesophageal cancer where ALX148 was well tolerated in combination with an anti-HER2 specific antibody and chemotherapy with no maximum tolerated dose reached. ALX Oncology plans to continue the advancement of ALX148 as a potential treatment for a range of solid tumor indications and is currently also in development in patients with higher risk myelodysplastic syndromes (ASPEN-02).

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody currently in a registration-enabling clinical trial for refractory HER2+ biliary tract cancer as well as several Phase 2 clinical trials for HER2+ gastroesophageal and breast cancers. Zymeworks’ second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For more information, visit www.zymeworks.com.

About ALX Oncology

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of ALX148 for the treatment of a range of solid tumor indications and myelodysplastic syndromes. For more information, please visit ALX Oncology’s website at www.alxoncology.com.

Zymeworks Cautionary Note Regarding Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements that relate to Zymeworks’ expectations regarding the beneficial characteristics, safety, and therapeutic effects of zanidatamab, its planned trials combining zanidatamab and ALX148, the potential benefits of that combination, and other information that is not historical information. When used herein, words such as “will”, “may”, “plan”, “potential”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation, market conditions and the factors described under “Risk Factors” in Zymeworks’ Quarterly Report on Form 10-Q for its quarter ended September 30, 2020 (a copy of which may be obtained at www.sec.gov and www.sedar.com). Consequently, forward-looking statements should be regarded solely as Zymeworks’ current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Zymeworks cannot guarantee future results, events, levels of activity, performance or achievements. Zymeworks does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

ALX Oncology Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on ALX Oncology’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause its actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding ALX Oncology’s clinical pipeline and expectations regarding the beneficial characteristics, safety, efficacy and therapeutic effects of ALX148. These and other risks are described more fully in ALX Oncology’s filings with the Securities and Exchange Commission (“SEC”), including ALX Oncology’s Quarterly Report on Form 10-Q, filed with the SEC on November 12, 2020, and other documents that ALX Oncology subsequently files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Zymeworks Inc.

Investor Inquiries

Ryan Dercho, Ph.D.

(604) 678-1388

[email protected]

Tiffany Tolmie

(604) 678-1388

[email protected]

Media Inquiries

Mary Klem

(604) 678-1388

[email protected]

ALX Oncology

Investor Inquiries

Peter Garcia

Chief Financial Officer, ALX Oncology

(650) 466-7125 Ext. 113

[email protected]

Argot Partners

(212)-600-1902

[email protected]

Media Inquiries

Karen Sharma

MacDougall

(781) 235-3060

[email protected]

KEYWORDS: California United States North America Canada

INDUSTRY KEYWORDS: Biotechnology Health Pharmaceutical Clinical Trials Oncology

MEDIA:

Logo
Logo
Logo
Logo
Posted on

Camden Property Trust Announces Participation in Nareit’s REITworld 2020 Annual Conference

Camden Property Trust Announces Participation in Nareit’s REITworld 2020 Annual Conference

HOUSTON–(BUSINESS WIRE)–
Camden Property Trust (NYSE: CPT) (the “Company”) announced today that it will participate in Nareit’s REITworld 2020 Annual Conference which is being held virtually November 17-19, 2020. Camden’s roundtable discussion has been scheduled for Wednesday, November 18, 2020 at 1:45 PM Eastern Time. The event will be webcast live in a listen-only mode and can be accessed by registering for the event at https://reit.cventevents.com/event/2e1cd484-8bec-4877-ad65-73cd599730f8/regProcessStep1. An audio archive of the event will be available on the Company’s website at camdenliving.com in the Investors section on or after Friday, November 20, 2020. A copy of Camden’s most recent investor presentation will also be available in the Investors section of the Company’s website.

Camden Property Trust, an S&P 400 Company, is a real estate company primarily engaged in the ownership, management, development, redevelopment, acquisition, and construction of multifamily apartment communities. Camden owns interests in and operates 165 properties containing 56,383 apartment homes across the United States. Upon completion of 9 properties currently under development, the Company’s portfolio will increase to 59,104 apartment homes in 174 properties. Camden has been recognized as one of the 100 Best Companies to Work For® by FORTUNE magazine for 13 consecutive years, most recently ranking #18. The Company also received a Glassdoor Employees’ Choice Award in 2020, ranking #25 for large U.S. companies.

For additional information, please contact Camden’s Investor Relations Department at (713) 354-2787 or access our website at camdenliving.com.

Kim Callahan, 713-354-2549

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Residential Building & Real Estate Commercial Building & Real Estate Construction & Property REIT

MEDIA:

Logo
Logo
Posted on

Slack Announces Date of Third Quarter Fiscal Year 2021 Financial Results

Slack Announces Date of Third Quarter Fiscal Year 2021 Financial Results

SAN FRANCISCO–(BUSINESS WIRE)–
Slack Technologies, Inc. (NYSE:WORK) today announced that it will report its financial results for the third quarter of fiscal year 2021, ended October 31, 2020, following the close of the U.S. markets on Wednesday, December 9, 2020. Slack will host a conference call that day at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) to discuss the results.

To access the conference call, participants need to register in advance online at http://www.directeventreg.com/registration/event/5993745. A live webcast of the conference call will be available on the Slack Investor Relations website, investor.slackhq.com. Following the completion of the call, a replay will also be made available at investor.slackhq.com.

About Slack

Slack has transformed business communication. It’s the leading channel-based messaging platform, used by millions to align their teams, unify their systems, and drive their businesses forward. Only Slack offers a secure, enterprise-grade environment that can scale with the largest companies in the world. It is a new layer of the business technology stack where people can work together more effectively, connect all their other software tools and services, and find the information they need to do their best work. Slack is where work happens.

Slack and the Slack logo are trademarks of Slack Technologies, Inc. or its subsidiaries in the U.S. and/or other countries. Other names and brands may be claimed as the property of others.

Jesse Hulsing

Investor Relations

[email protected]

Steve Sharpe

Media Relations

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Data Management Technology Mobile/Wireless Software Networks Internet

MEDIA:

Logo
Logo
Posted on

The Toro Company to Announce Fiscal 2020 Full-Year Results

The Toro Company to Announce Fiscal 2020 Full-Year Results

BLOOMINGTON, Minn.–(BUSINESS WIRE)–
The Toro Company (NYSE: TTC) today announced that it will release its fiscal 2020 full-year results on Wednesday, December 16, at approximately 7:30 a.m. CST. The full text of Toro’s earnings release will be available at that time at www.thetorocompany.com/invest. The company also will hold an earnings conference call at 10 a.m. CST that day.

A live, listen-only webcast of the earnings conference call will be available at www.thetorocompany.com/invest. Visitors are encouraged to go to the website in advance of the call to register, and download and install any necessary audio software.

For those unable to listen to the live webcast, a replay will be available at www.thetorocompany.com/invest.

About The Toro Company

The Toro Company (NYSE: TTC) is a leading worldwide provider of innovative solutions for the outdoor environment including turf and landscape maintenance, snow and ice management, underground utility construction, rental and specialty construction, and irrigation and outdoor lighting solutions. With sales of $3.1 billion in fiscal 2019, The Toro Company’s global presence extends to more than 125 countries through a family of brands that includes Toro, Ditch Witch, Exmark, BOSS Snowplow, Ventrac, American Augers, Subsite Electronics, HammerHead, Trencor, Unique Lighting Systems, Irritrol, Hayter, Pope, Lawn-Boy and Radius HDD. Through constant innovation and caring relationships built on trust and integrity, The Toro Company and its family of brands have built a legacy of excellence by helping customers care for golf courses, sports fields, construction sites, public green spaces, commercial and residential properties and agricultural operations. For more information, visit www.thetorocompany.com.

Investor Relations

Nicholas Rhoads

Managing Director, Investor Relations

(952) 887-8865, [email protected]

Media Relations

Branden Happel

Senior Manager, Public Relations

(952) 887-8930, [email protected]

KEYWORDS: Minnesota United States North America

INDUSTRY KEYWORDS: Commercial Building & Real Estate Construction & Property Building Systems Automotive Manufacturing Landscape Other Construction & Property Manufacturing Residential Building & Real Estate

MEDIA:

Logo
Logo
Posted on

Universal Insurance Holdings Declares Regular and Special Cash Dividends Totaling 29 Cents Per Share

Universal Insurance Holdings Declares Regular and Special Cash Dividends Totaling 29 Cents Per Share

FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–
Universal Insurance Holdings, Inc. (NYSE: UVE) announced today that its Board of Directors has declared a quarterly regular and special cash dividend, together totaling 29 cents per share of common stock, payable December 18, 2020 to shareholders of record as of the close of business on December 11, 2020. The 29 cents per share dividend consists of a regular quarterly cash dividend of 16 cents per share and a special cash dividend of 13 cents per share, bringing the total regular and special dividends declared in 2020 to 77 cents per share.

About Universal Insurance Holdings, Inc.

Universal Insurance Holdings (UVE) is a holding company offering property and casualty insurance and value-added insurance services. We develop, market, and write insurance products for consumers predominantly in the personal residential homeowners lines of business and perform substantially all other insurance-related services for our primary insurance entities, including risk management, claims management and distribution. We sell insurance products through both our appointed independent agents and through our direct online distribution channels in the United States across 19 states (primarily Florida). Learn more at UniversalInsuranceHoldings.com.

Investor Relations Contact:

Rob Luther, 954-958-1200 ext. 6750

VP, Corporate Development, Strategy & IR

[email protected]

Media Relations Contact:

Andy Brimmer / Mahmoud Siddig, 212-355-4449

Joele Frank, Wilkinson Brimmer Katcher

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: Insurance Professional Services

MEDIA:

Logo
Logo